However, retrospective analysis showed that SGLT2 was not significantly expressed in pancreatic cancer, but SGLT1 was significantly overexpressed; the median overall and progression-free survival of patients with high expression of SGLT1 was significantly longer than that of patients with low expression of SGLT1, suggesting that high expression of SGLT1 is an independent predictor of better prognosis (41). The gene discussed is SLC5A2; the disease is pancreatic neoplasm.